Bioequivalence of two pharmaceutical forms of diltiazem.
Diltiazem, a calcium-channel blocking agent, has been shown to be a potent coronary vasodilator used in the treatment of ischaemic heart disease. The present study was conducted to compare the bioavailability of regular 60 mg tablets administered every 6 h with sustained release capsules of 120 mg administered every 12 h. High-performance liquid chromatographic analysis was carried out for determination of diltiazem and one of its metabolites desacetyldiltiazem in six male patients. The relative bioavailability of this sustained-release pharmaceutical form did not show any significant difference with that of tablets.
Rubio
M
M
School of Pharmacy and Biochemistry, Buenos Aires University, Argentina.
Masana
M I
MI
Garcilazo
E
E
de los Santos
A R
AR
di Girolamo
G
G
D002214:Capsules; D002851:Chromatography, High Pressure Liquid; D003692:Delayed-Action Preparations; D004110:Diltiazem / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D013607:Tablets; D013810:Therapeutic Equivalency
D002214:Capsules; D003692:Delayed-Action Preparations; D013607:Tablets; D004110:Diltiazem